About golimumab
Tumor necrosis factor inhibitor
Used for
- Rheumatoid arthritis, usually with methotrexate
- Psoriatic arthritis
- Ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Ulcerative colitis
Usual adult dose
Usually 50 mg under the skin once monthly for arthritis; ulcerative colitis dosing differs and may require specialist adjustment.
Usual dose in children
For polyarticular juvenile idiopathic arthritis, usually 30 mg/m² under the skin monthly, maximum 50 mg; approved age and use vary by country.
Common side effects
- Upper respiratory infections
- Injection-site reactions
- Nausea
- Increased liver enzymes
Important warnings
- Can cause serious infections, including tuberculosis; screening is required before treatment.
- Avoid live vaccines during treatment.
- May worsen heart failure or cause rare nervous system disorders.
- Rarely associated with cancers, blood disorders, or severe liver injury.
Pregnancy
May be continued when clinically needed; discuss timing with a specialist because it crosses the placenta, especially later in pregnancy.
Breastfeeding
Small amounts may enter breast milk; limited evidence suggests low infant absorption. Discuss use with a clinician.
Interactions
- Other biologic immune-suppressing medicines, including anakinra or abatacept
- Live vaccines
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.